argenex SE $ARGX Shares Sold by NEOS Investment Management LLC

NEOS Investment Management LLC reduced its position in shares of argenex SE (NASDAQ:ARGX) by 26.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,031 shares of the company’s stock after selling 722 shares during the period. NEOS Investment Management LLC’s holdings in argenex were worth $1,498,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Bessemer Group Inc. grew its holdings in argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after acquiring an additional 47 shares during the period. Mather Group LLC. purchased a new stake in shares of argenex in the 3rd quarter worth about $50,000. TD Private Client Wealth LLC grew its stake in argenex by 750.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after acquiring an additional 75 shares during the last quarter. MAI Capital Management increased its holdings in argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares in the last quarter. Finally, Financial Consulate Inc. acquired a new stake in shares of argenex in the third quarter valued at approximately $75,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Robert W. Baird downgraded argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. Zacks Research lowered shares of argenex from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 22nd. Wells Fargo & Company lifted their price objective on argenex from $1,264.00 to $1,317.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Truist Financial upped their price objective on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada lifted their target price on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and a consensus target price of $986.78.

argenex Trading Down 0.3%

Shares of ARGX stock opened at $844.41 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market capitalization of $52.25 billion, a PE ratio of 36.26, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. The firm has a fifty day simple moving average of $831.22 and a 200-day simple moving average of $805.88.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.